Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This article discusses the immune mechanisms involved in alopecia areata, focusing on T-cell activity and cytokine-driven JAK signaling, but reports no new clinical results.

This case series found that oral tofacitinib treatment in eight adolescents with alopecia universalis led to significant regrowth of hair, though relapse is likely after stopping therapy.

Deuruxolitinib effectively promotes hair regrowth in alopecia areata.

This source reports that recent research highlights the effectiveness and tolerability of oral JAK inhibitors for treating moderate to severe alopecia areata, although further placebo-controlled studies are needed to confirm their long-term safety and efficacy.

In this study, two patients with severe alopecia areata who did not respond well to oral tofacitinib showed more than 50% hair regrowth after a single dose of intramuscular triamcinolone acetonide.

In this study using a mouse model with alopecia areata, the researchers found that ruxolitinib enhances hair regrowth by inhibiting the JAK-STAT signaling pathway, reducing inflammation and oxidative stress, and decreasing apoptosis, which supports its clinical effectiveness in treating this condition.

This letter reports a series of cases where the use of ruxolitinib at a lower dose than previously studied led to hair regrowth in patients with severe alopecia areata.

This study suggests that erlotinib exacerbates inflammation in a mouse model of skin disease and that IL-1 inhibition could mitigate skin-related side effects of EGFR inhibitors.

This study reports that combining baricitinib with low-dose cyclosporine and steroids resulted in effective and safe treatment for a case of alopecia totalis, maintaining hair regrowth without adverse effects.

In this case report, the authors concluded that cutaneous lupus erythematosus was induced by the PD-1 inhibitor tislelizumab during treatment for metastatic lung adenocarcinoma, despite initial remission and treatment adjustments.

The authors concluded that incorporating routine endocrinology consultations into transplant care could address CNI-related endocrine toxicities, but prospective studies are needed to assess the impact on graft and patient survival.

This article in the International Journal of Dermatology reports on a case series where the drug upadacitinib was used to treat patients with recalcitrant lichen planopilaris, but no abstract or detailed results are provided to assess its efficacy or safety fully.

In this study, upadacitinib was reported as effective in rapidly treating psoriasiform eczema in five male patients and showed varying degrees of effectiveness on other immune-mediated comorbidities like alopecia areata, vitiligo, ulcerative colitis, and hidradenitis suppurativa.

This study concluded that while remote interventions using digital health technology can enhance health-related outcomes, medication adherence, and economic status in kidney transplant recipients, their effect on tacrolimus concentration is not clearly understood.

This review found that JAK/STAT pathway inhibitors, such as tofacitinib and ruxolitinib, led to symptom improvement in all observed atopic dermatitis cases, but responses were mixed for vitiligo and alopecia areata, with a generally mild safety profile reported.

This case study documents a 55-year-old male with advanced NSCLC who experienced toe-predominant paronychia and a papulopustular rash following dacomitinib treatment, with the causality tools indicating a "probable" link, yet the therapy continued successfully without dosage alteration.

This study found that JAK inhibitors for alopecia areata showed promising response rates, with 72.4% of 289 cases responding, and oral administration achieving better outcomes than topical treatment, but recurrence occurred when treatment stopped. Further large-scale studies are needed to confirm these findings.

This case study reports that tofacitinib effectively treated alopecia areata in a patient with Crohn's disease and maintained her Crohn's disease management.

This study conducted a survey among consultant dermatologists in Ireland to explore their use of JAK inhibitors for treating alopecia areata, acknowledging challenges posed by the lack of global guidelines and long-term safety data.

This case study reports that tofacitinib led to remission of psoriasis but did not improve alopecia universalis in one patient, suggesting varied responses in treating such conditions.

Deuruxolitinib is generally safe for treating alopecia areata.

This retrospective study observed that switching from tofacitinib to baricitinib improved hair growth in patients with alopecia areata, particularly for previous non-responders, and noted fewer side effects with baricitinib.

Dermatologists are hesitant to prescribe Janus kinase inhibitors for alopecia areata due to safety concerns and lack of knowledge.

Baricitinib effectively stops hair loss and promotes regrowth in acute alopecia areata.

This article addresses the pathogenesis of alopecia areata and discusses the emerging role of oral and topical JAK inhibitors in its treatment, but reports no new clinical findings.

In this case report, a female patient with Graham-Little-Piccardi-Lassueur Syndrome and hidradenitis suppurativa showed significant improvement in symptoms, including hair loss and lesions, after six months of treatment with tofacitinib, with no recurrence or adverse effects over a two-year follow-up.

This study found that systemic treatment with DS77754007, a KLK5 inhibitor, improved skin symptoms in a mouse model of Netherton Syndrome more effectively than certain antibody treatments, suggesting KLK5 inhibition as a promising therapeutic approach for this condition.

This review discusses recent findings on the efficacy of JAK inhibitors for treating alopecia areata, highlighting their role in reversing hair loss by targeting the JAK-STAT signaling pathway, though questions about their effectiveness and safety remain.

This review discusses cyclosporine A's mechanisms of action and side effects compared to tacrolimus in renal transplantation, but it reports no new experimental results; the authors highlight implications for cardiovascular risk management.

In this case report, a 60-year-old woman with alopecia areata and type 1 diabetes experienced hypoglycemic seizures after starting baricitinib, though reducing the dose alleviated these episodes; the study highlights the need for caution and glucose monitoring when using JAK inhibitors in at-risk patients.